Alan L. Epstein|USC Keck School of Medicine| USA| Biosimilars 2015 | Conference Series LLC
4th International Conference and Exhibition on Biologics and Biosimilars October 26-28, 2015 Baltimore, USA
Scientific Talk On: ERBITUX BIOSIMILAR
Click here for Abstract and Biography:http://biosimilars-biologics.pharmaceuticalconferences.com/abstract/2015/erbitux-biosimilar
Conference Series LLC (3000+ Global Events): conferenceseries.com
Global Medical Conferences: conferenceseries.com
Global Nursing Conferences: nursingconference.com
Global Pharmaceutical Conferences: pharmaceuticalconferences.com
Global Cancer Conferences: cancersummit.org
Global Diabetes Conferences: diabetesexpo.com
Global Dental Conferences: dentalcongress.com
700+ Open Access Journals: omicsonline.org
Dr. Epstein received his BA degree from Wesleyan University, Middletown, CT and his MD/PhD degrees from the Medical Scientist Training Program at Stanford University School of Medicine under the tutelage of the late Henry Kaplan. He is currently Professor of Pathology at the USC Keck School of Medicine since 1984 and has over 160 publications and 30 patents in the field of tumor cell biology and cancer immunotherapy. He is expert in the development of novel cancer cell lines, monoclonal antibodies, antibody fusion proteins, and immunodiagnostics useful for the treatment and diagnosis of lymphomas and solid tumors.
Supported by a NCI SBIR contract, a biosimilar Erbitux antibody, designated ch225, has been developed over the last three years for the immunotherapy of EGFR+, KRAS mutation negative tumors. In 2011, there were 141,210 new cases of colon and rectal cancers and 49,380 deaths in the USA accounting for the 12.2 billion dollars spent on colorectal cancer treatment alone. In addition,head and neck cancers account for 45,000 additional cases that are eligible for Erbitux treatment. These statistics show that Erbitux is an important treatment modality especially since its therapeutic effects against other tumors such as non-small cell lung cancer has been demonstrated.After extensive analyses of commercial Erbitux, a biosimilar antibodywas developed using genetic engineering methods. Our initial studies demonstratedthat ch225 has the same primary amino acid sequence, charge distribution, and glycosylation profile as Erbitux required for its biosimilarity. In addition, the potencyof ch225 against EGFR positive and negative cell linesand PK/PD studies closely matched commercial Erbitux batches both in vitro and in vivo. Based upon these results, extensive cloning methods were used to develop a high yielding subclonein serum free medium which produces over 1mg/ml of antibody stable out to 35 generations. A growth supplement was also identified which increased its productivity enabling the accumulation of 4 x 107 cells/ml with over 98% viability. In conclusion, despite numerous difficulties encountered during the course of this work, a biosimilar Erbitux has been produced and readied for cGMP and clinical trials.